Articles

Long-form writing on ibogaine, recovery, and the science behind the work.

Our Articles

Graphic for the appeal 'We owe her more: Support Norma Lotsof', a composite of Charles D. Johnston beside an archival image of Howard and Norma Lotsof over a jungle background.

We Owe Norma Lotsof More Than Thanks

Norma Lotsof, Howard Lotsof's widow, was there in the early days of the ibogaine movement. Charles Johnston asks the community that benefits from that work, clinics included, to support the fundraiser for her.

October 11, 2026

The Nekawa Report: Who gets to own ibogaine? Charles D. Johnston beside a card comparing Texas's 20%+ share of the revenue with Gabon's 0%.

Who gets to own ibogaine? Texas's $50 million, patents and Gabon

Texas set aside $50 million for ibogaine trials and hasn't spent any of it. Drug companies are racing to patent ibogaine-like molecules, a new study puts the side effects in plain view, and Gabon has moved to ban iboga exports. Charles Johnston answers DJ's questions about who stands to own ibogaine's future.

October 11, 2026

The Nekawa Report: Who's getting rich off ibogaine? Charles Johnston beside a New York Post clipping and a price card, clinical ibogaine $20,000, traditional ibogaine about $3,000.

Who's getting rich off ibogaine? A response to the New York Post

The New York Post says CEOs are paying up to $20,000 for ibogaine in Cancún. Charles Johnston asks who is getting rich, and why the Gabonese communities who kept iboga alive are left out of the story.

October 9, 2026

Charles Johnston by the river at Nekawa with the words Why 28 days?

Why 28 days? Preparation, integration, and the jungle in ibogaine care

Most ibogaine programs last a week or less. Charles Johnston on why Nekawa only runs 28-day residential programs: preparation before the medicine, integration that you practice, and time in the jungle.

October 2, 2026

Charles Johnston in the rainforest beside the title "Iboga vs Ibogaine"

Ibogaine versus Iboga and the difference between plant and molecule

Iboga is a plant. Ibogaine is one of its alkaloids. Charles Johnston on what changes when a plant tradition becomes a single molecule, what full spectrum does and does not tell you, and why the spiritual side of this medicine should come first, with medical care built around it.

October 1, 2026

Charles Johnston beside the New York Times headline "Americans Encounter Risks at Psychedelic Clinics Abroad", asking whether the ibogaine industry is broken

The New York Times Just Called Out the Ibogaine Treatment Industry. Here's What They Missed.

The Times found real problems in the ibogaine industry: four-day programs, sedatives on arrival, testimonials filmed inside the experience. Charles Johnston, recording from Nekawa in Brazil, says the reporting is fair and the diagnosis is incomplete.

September 16, 2026

The Ibogaine Executive Order: Can We Prevent Medical Colonization? Now

The White House executive order on psychedelic medicine is a historic moment for ibogaine — and a blueprint for appropriating a sacred Indigenous sacrament without acknowledgment, remuneration, or respect for the people who carried it here.

April 18, 2026

The Surprising Modern History of Ibogaine-today

Learn about the history of Ibogaine treatment and how it's used in the modern day.

August 20, 2025